Security
NuCana plc American Depositary Share · NCNA
NCNANASDAQotherCurrentCIK 1709626Updated Oct 6, 2026
Name history
NuCana BioMed Ltd · through Aug 4, 2017
NCNA price & chart
Loading TradingView…
NASDAQ:NCNA on TradingView ↗About the company
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a …
In the news
No coverage from other publishers is available.
Recent filings
Show 1 more recent filings
Financials
FY 2025 · GBPSource
Source
cash flow · annual statements
| Line item | Q4 2021 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q1 2021 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossGBP | — | -8,041,000Source | -24,114,000Source | -6,995,000Source | -5,414,000Source | -3,892,000Source | -9,087,000Source | -9,761,000Source | -29,353,000Source | -18,997,000Source | -27,632,000Source | -32,021,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForDeferredTaxOfPriorPeriodsGBP | — | — | — | — | — | — | — | — | 3,535,000Source | 1,746,000Source | 2,715,000Source | 2,711,000Source |
| AdjustmentsForFinanceIncomeGBP | — | — | — | — | — | — | — | 24,000Source | 386,000Source | 358,000Source | 754,000Source | 669,000Source |
| AdjustmentsForIncomeTaxExpenseGBP | — | — | — | — | — | — | — | -1,702,000Source | -1,168,000Source | -3,454,000Source | -4,398,000Source | -6,432,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableGBP | — | — | — | — | — | — | — | 1,285,000Source | -2,183,000Source | -670,000Source | -1,428,000Source | 2,974,000Source |
| AdjustmentsForSharebasedPaymentsGBP | — | — | — | — | — | — | — | 1,795,000Source | 10,028,000Source | 1,646,000Source | 3,857,000Source | 4,890,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsGBP | — | — | — | — | — | — | — | 664,000Source | 194,000Source | -369,000Source | 1,176,000Source | -5,014,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesGBP | — | — | — | — | — | — | — | — | -3,988,000Source | -4,015,000Source | -5,595,000Source | -7,220,000Source |
| IncreaseDecreaseInWorkingCapitalGBP | — | — | — | — | — | — | — | -726,000Source | 3,672,000Source | 2,183,000Source | 1,281,000Source | -3,723,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP | — | — | — | — | — | — | — | 74,000Source | 54,000Source | 223,000Source | 270,000Source | 227,000Source |
| ProceedsFromIssuingSharesGBP | — | — | — | — | — | — | — | 198,000Source | 20,185,000Source | 8,729,000Source | 249,000Source | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesGBP | — | — | — | — | — | — | — | 138,000Source | 193,000Source | 289,000Source | 474,000Source | 506,000Source |
| InterestReceivedClassifiedAsOperatingActivities | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2021 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q1 2021 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Financial Items | ||||||||||||
| AdministrativeExpenseGBP | — | 2,277,000Source | 4,523,000Source | 1,509,000Source | 1,754,000Source | 1,889,000Source | 2,075,000Source | 2,104,000Source | 8,096,000Source | 4,988,000Source | 6,063,000Source | 7,291,000Source |
| BasicEarningsLossPerShareGBP/shares | — | — | 0Source | -0.12Source | -0.1Source | -0.07Source | -0.17Source | — | 0Source | -0.26Source | -0.53Source | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossGBP | — | — | — | — | — | — | — | — | -12,000Source | 32,000Source | -47,000Source | -34,000Source |
| DepreciationRightofuseAssetsGBP | — | — | — | — | — | — | — | — | 65,000Source | 207,000Source | 212,000Source | 251,000Source |
| DilutedEarningsLossPerShareGBP/shares | — | — | 0Source | -0.12Source | -0.1Source | -0.07Source | -0.17Source | — | 0Source | -0.26Source | -0.53Source | — |
| EmployeeBenefitsExpenseGBP | — | — | — | — | — | — | — | — | 15,056,000Source | 7,025,000Source | 10,819,000Source | 12,353,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesGBP | — | 1,300,000Source | 8,000,000Source | 700,000Source | 1,100,000Source | 1,200,000Source | 1,800,000Source | 1,800,000Source | 10,000,000Source | 1,600,000Source | 3,900,000Source | 4,900,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedGBP | — | — | — | — | — | — | — | — | 520,000Source | 0Source | 4,000Source | 480,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedGBP | — | — | — | — | — | — | — | — | 54,000Source | 223,000Source | 270,000Source | 227,000Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesGBP | — | — | — | — | — | — | — | — | 0Source | 0Source | 6,000Source | 6,000Source |
| FinanceCostsGBP | — | — | 12,648,000Source | 0Source | — | — | — | — | 12,648,000Source | — | — | — |
| FinanceIncomeGBP | — | 22,000Source | 35,000Source | 85,000Source | 178,000Source | 132,000Source | 35,000Source | 24,000Source | 386,000Source | 358,000Source | 754,000Source | 669,000Source |
| IncomeTaxExpenseContinuingOperationsGBP | — | -1,911,000Source | -328,000Source | -1,272,000Source | -685,000Source | -1,194,000Source | -1,585,000Source | -1,702,000Source | -1,168,000Source | -3,454,000Source | -4,398,000Source | -6,432,000Source |
| InterestExpenseOnLeaseLiabilitiesGBP | — | — | — | — | — | — | — | 6,000Source | 20,000Source | 17,000Source | 29,000Source | 21,000Source |
| OtherIncomeGBP | — | — | — | — | — | — | — | — | 2,692,000Source | — | — | — |
| ProfitLossBeforeTaxGBP | — | -9,952,000Source | -24,442,000Source | -8,267,000Source | -6,099,000Source | -5,086,000Source | -10,672,000Source | -11,463,000Source | -30,521,000Source | -22,451,000Source | -32,030,000Source | -38,453,000Source |
| ProfitLossFromOperatingActivitiesGBP | — | -9,974,000Source | -11,829,000Source | -8,352,000Source | -6,277,000Source | -5,218,000Source | -10,707,000Source | -11,487,000Source | -20,110,000Source | -22,809,000Source | -32,784,000Source | -39,122,000Source |
| ResearchAndDevelopmentExpenseGBP | — | 8,971,000Source | 7,104,000Source | 6,769,000Source | 3,959,000Source | 6,406,000Source | 8,523,000Source | 8,706,000Source | 12,737,000Source | 18,017,000Source | 25,062,000Source | 36,426,000Source |
Filing attachments
d285861dex991.htm · 6-K · 2026-09-30
Exhibit 99.1 NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe NUC-7738 is protected by over 85 issued patents worldwide Edinburgh, United Kingdom, September 30, 2026 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”) has granted an important patent covering the composition of matter for NUC-7738. This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currentl…
Read attachment ↗d140331dex991.htm · 6-K · 2026-08-13
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended For the Six Months Ended June 30, June 30, …
Read attachment ↗d140331dex992.htm · 6-K · 2026-08-13
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on August 13, 2026. We also recommend that you read our discussio…
Read attachment ↗d247626dex991.htm · 6-K · 2026-06-01
Exhibit 99.1 NuCana Appoints Ian Webster as Chief Financial Officer Edinburgh, United Kingdom, June 1, 2026 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial Officer, effective today. Ian has served as Interim Chief Financial Officer since June 2025 and was previously Director of Finance si…
Read attachment ↗d96757dex991.htm · 6-K · 2026-05-14
Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2026 2025 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗d96757dex992.htm · 6-K · 2026-05-14
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on May 14, 2026. We also recommend that you read our discussion a…
Read attachment ↗